AIM: To characterize the effect of donor and recipient CYP3A4, CYP3A5 and ABCB1 genotypes as well as relevant patient characteristics on tacrolimus pharmacokinetics in pediatric liver transplantation. PATIENTS & METHODS: Data from 114 pediatric liver transplant recipients were retrospectively collected during the first 3 months following transplantation. Population pharmacokinetic analysis was performed using nonlinear mixed effects modeling, including characterization of influential covariates. RESULTS: A two-compartment model with first order elimination best fitted the data. Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively. Time post-transplantation, recipient age, donor CYP3A5 and CYP3A4 genotypes and fluconazole administration significantly influenced tacrolimus apparent clearance while bodyweight influenced volume of distribution. CONCLUSION: The proposed model displayed acceptable fitting performances and enabled identification of statistically significant and clinically relevant covariates on tacrolimus pharmacokinetics in the early pediatric post liver transplantation period.
AIM: To characterize the effect of donor and recipient CYP3A4, CYP3A5 and ABCB1 genotypes as well as relevant patient characteristics on tacrolimus pharmacokinetics in pediatric liver transplantation. PATIENTS & METHODS: Data from 114 pediatric liver transplant recipients were retrospectively collected during the first 3 months following transplantation. Population pharmacokinetic analysis was performed using nonlinear mixed effects modeling, including characterization of influential covariates. RESULTS: A two-compartment model with first order elimination best fitted the data. Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively. Time post-transplantation, recipient age, donorCYP3A5 and CYP3A4 genotypes and fluconazole administration significantly influenced tacrolimus apparent clearance while bodyweight influenced volume of distribution. CONCLUSION: The proposed model displayed acceptable fitting performances and enabled identification of statistically significant and clinically relevant covariates on tacrolimus pharmacokinetics in the early pediatric post liver transplantation period.
Authors: K A Birdwell; B Decker; J M Barbarino; J F Peterson; C M Stein; W Sadee; D Wang; A A Vinks; Y He; J J Swen; J S Leeder; Rhn van Schaik; K E Thummel; T E Klein; K E Caudle; I A M MacPhee Journal: Clin Pharmacol Ther Date: 2015-06-03 Impact factor: 6.875
Authors: Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore Journal: J Clin Pharmacol Date: 2018-05-18 Impact factor: 3.126
Authors: Jean-Baptiste Woillard; Michel Mourad; Michael Neely; Arnaud Capron; Ron H van Schaik; Teun van Gelder; Nuria Lloberas; Dennis A Hesselink; Pierre Marquet; Vincent Haufroid; Laure Elens Journal: Front Pharmacol Date: 2017-06-08 Impact factor: 5.810
Authors: D J A R Moes; S A S van der Bent; J J Swen; T van der Straaten; A Inderson; E Olofsen; H W Verspaget; H J Guchelaar; J den Hartigh; B van Hoek Journal: Eur J Clin Pharmacol Date: 2015-10-31 Impact factor: 2.953
Authors: Miriam G Mooij; Anne T Nies; Catherijne A J Knibbe; Elke Schaeffeler; Dick Tibboel; Matthias Schwab; Saskia N de Wildt Journal: Clin Pharmacokinet Date: 2016-05 Impact factor: 6.447